Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06682247

A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer

This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced colorectal cancer patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Colorectal Cancer Metastatic

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged≥18 years
  • Histology-confirmed metastatic CRC (mCRC);
  • ECOG 0~2
  • At least one efficacy evaluation
  • Life expectancy of at least 3 months.

Exclusion criteria

  • Lack of follow-up data.
  • Chidamide stopped after less than two cycles.
  • Serious comorbidities that interfere with the efficacy or safety analysis

Treatment and study plan

Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors

Drug

Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors

Primary outcomes

  1. Progression-free survival(PFS)

    Time frame: 2 years

Secondary outcomes

  1. Objective Response Rate（ORR）

    Time frame: 2 years

  2. Clinical Benefit Rate (CBR)

    Time frame: 2 years

  3. Disease Control Rate （DCR）

    Time frame: 2 years

  4. Overall survival (OS)

    Time frame: 2 years

Study contacts

Contact information is provided by the study sponsor or research team.

feng wang

CONTACT

[email protected]

020-87343088

Sponsors and collaborators

Lead sponsor

Feng Wang

Other

Registry information

Official study title

A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in the Treatment of Microsatellite Stable Advanced Colorectal Cancer

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Nov 12, 2024
Registry last updated
Nov 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.